Phase I study of oncolytic vaccinia virus GL-ONC1 in patients with peritoneal carcinomatosis.

CONCLUSIONS: GL-ONC1 was well tolerated when administered into the peritoneal cavity of patients with advanced stage PC. Efficient tumor cell infection, in-patient virus replication as well as onco-lysis were limited to treatment cycle 1. (ClinicalTrials.gov number, NCT01443260).
PMID: 29773661 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - May 17, 2018 Category: Cancer & Oncology Authors: Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, Königsrainer A, Möhle R, Nann D, Fend F, Pfannenberg C, Bitzer M, Malek NP Tags: Clin Cancer Res Source Type: research